| Overview |
| bsm-61709r-TR |
| CDT2 Recombinant Antibody |
| WB, IHC-P, IHC-F, IF, Flow-Cyt, ICC/IF |
| Human, Mouse, Rat |
| Specifications |
| Unconjugated |
| Rabbit |
| KLH conjugated synthetic peptide derived from human CDT2 |
| Recombinant |
| IgG |
| Lot dependent |
| Purified by Protein A. |
| 0.01M TBS (pH 7.4), 1% BSA, 0.02% Proclin 300, and 50% Glycerol |
| Shipped at 4C. Store at -20C for one year. Avoid repeated freeze/thaw cycles. |
| Target |
| 51514 |
| Q9NZJ0 |
| Cytoplasm, Nucleus, Cell membrane |
| CDW1; DCAF2; Dtl; L2DTL; RAMP. |
| Substrate-specific adapter of a DCX (DDB1-CUL4-X-box) E3 ubiquitin-protein ligase complex required for cell cycle control, DNA damage response and translesion DNA synthesis. The DCX(DTL) complex, also named CRL4(CDT2) complex, mediates the polyubiquitination and subsequent degradation of CDT1, CDKN1A/p21(CIP1), FBH1, KMT5A and SDE2. |
| Application Dilution |
| WB |
1:300-5000 |
| IHC-P |
1:200-400 |
| IHC-F |
1:100-500 |
| IF |
|
| Flow-Cyt |
1ug/Test |
| ICC/IF |
1:50-100 |